NRx Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, NRx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $42. The average 1-year stock price forecast is 957.93% higher than the current stock price, while the lowest is $25 (+529.72%) and the highest is $49 (+1,134.26%).

Price Target: $42 (+957.93%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$25	$42	$47	$49
Change	+529.72%	+957.93%	+1083.9%	+1134.3%

Analyst Ratings

The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	4	4	4	4	4	4
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	4	4	4	4	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $45	Buy	Reiterates	$45	+1,033.50%	May 28, 2026
Elemer Piros Lucid Capital	Lucid Capital	Buy Initiates $49	Buy	Initiates	$49	+1,134.26%	May 13, 2026
Jason Kolbert D. Boral Capital	D. Boral Capital	Buy Maintains $34	Buy	Maintains	$34	+756.42%	Apr 20, 2026
Thomas Shrader BTIG	BTIG	Buy Maintains $25	Buy	Maintains	$25	+529.72%	Mar 25, 2026
Edward Woo Ascendiant	Ascendiant	Buy Maintains $47 → $48	Buy	Maintains	$47 → $48	+1,109.07%	Dec 31, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

12.99M

from 1.23M

960.08%

from 1.23M

Revenue Next Year

204.07M

from 12.99M

1,471.44%

from 12.99M

EPS This Year

-0.36

from -1.34

EPS Next Year

0.50

from -0.36

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	1.23M	12.99M
Revenue Growth	-	-	-	-	-	960.08%
Gross Profit	-	-	-	-	720.00K	8.38M
Gross Margin	-	-	-	-	58.78%	64.50%
Operating Income	-94.43M	-44.34M	-27.59M	-19.70M	-16.19M	-16.86M
Net Income	-93.06M	-39.75M	-30.15M	-25.13M	-28.62M	-13.55M
EPS	-	-	-	-	-1.34	-0.36
Free Cash Flow	-89.80M	-28.24M	-11.47M	126.25K	-805.88K	-13.20M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	21.7M
Avg	13.0M
Low	4.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,671.4%
Avg	960.1%
Low	248.7%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.36
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-